Contract Research & Services
Clinical Trials

Clinical Trials News

View news from other Pharmaceutical sectors:
196-210 of 4334 results
Merck cholesterol drug reduces heart risk by 9% in study
By PBR Staff Writer
Merck’s cardiovascular treatment anacetrapib has reduced the risk of major coronary events in the REVEAL study.
Contract Research & Services > Clinical Trials > News
Apellis’ APL-2 meets primary endpoint in phase 2 study in patients with geographic atrophy
Apellis Pharmaceuticals’ complement C3 inhibitor, APL-2, met its primary endpoint in phase 2 clinical trial conducted on patients with geographic atrophy (GA) associated with age-related macular degeneration (AMD).
Contract Research & Services > Clinical Trials > News
Cancer Research UK launches clinical trial to test new cancer drug
Cancer Research UK has launched a clinical study to evaluate a new cancer drug in patients with advanced solid tumours in four centres across the UK through its Centre for Drug Development.
Contract Research & Services > Clinical Trials > News
Ultragenyx’ Ace-ER fails in phase 3 GNE Myopathy trial
Ultragenyx Pharmaceutical’s phase 3 study evaluating aceneuramic acid extended release (Ace-ER) in patients with GNE Myopathy (GNEM) failed to meet primary endpoint of showing a statistically significant difference in the upper extremity muscle strength composite score compared to placebo.
Contract Research & Services > Clinical Trials > News
ViraCyte announces positive phase 2 trial results
ViraCyte has announced publication of positive data from a Phase 2 clinical trial evaluating its most advanced T-cell immunotherapy product, Viralym-M.
Contract Research & Services > Clinical Trials > News
Boehringer initiates phase 1 trials of Zealand’s analogs for obesity and diabetes
By PBR Staff Writer
Zealand Pharma says that its partner Boehringer Ingelheim has launched phase 1 clinical trials to assess glucagon/GLP-1 agonist and an amylin analog as new treatment options for obesity and diabetes.
Contract Research & Services > Clinical Trials > News
Pfizer-led consortium begins trial of metastatic breast cancer treatment palbociclib
By PBR Staff Writer
Pfizer, along with Alliance Foundation Trials (AFT) and six other international cancer research groups, has commenced a phase 3 clinical study to assess palbociclib (Ibrance) for the treatment of patients with metastatic breast cancer.
Contract Research & Services > Clinical Trials > News
Ovid Therapeutics recruits first patient in phase 1b/2a trial of TAK-935/OV935 in adults with rare epilepsies
Ovid Therapeutics announced it has randomized the first patient in its Phase 1b/2a clinical trial of TAK-935, also known as OV935, in collaboration with Takeda Pharmaceutical Company Limited.
Contract Research & Services > Clinical Trials > News
Novartis, MMV begin patient trial of antimalarial compound in Africa
By PBR Staff Writer
Novartis and Medicines for Malaria Venture (MMV) have started a patient trial of antimalarial compound, KAF156, in Africa.
Contract Research & Services > Clinical Trials > News
US DOD to commence new trial with Pluristem's PLX-R18 cell therapy against ARS
Pluristem Therapeutics stated that a pilot study of its PLX-R18 cell therapy will be initiated by the US Department of Defense’s (DOD) Armed Forces Radiobiology Research Institute (AFRRI), part of the Uniformed Services University of Health Sciences (USU).
Contract Research & Services > Clinical Trials > News
Mateon’s ovarian cancer treatment CA4P shows favorable results in Focus study
By PBR Staff Writer
Mateon Therapeutics’ ovarian cancer treatment CA4P in combination with Roche’s bevacizumab (Avastin) has showed favorable results in the scheduled interim analysis of the ongoing phase 2/3 Focus study.
Contract Research & Services > Clinical Trials > News
Aradigm gets NIH grant for Linhaliq in pulmonary non-tuberculous mycobacteria treatment
The National Institute of Allergy and Infectious Diseases (NIAID) and National Institutes of Health (NIH) have awarded a Small Business Initiative Research (SBIR) grant to Aradigm to study the treatment of two pulmonary non-tuberculous mycobacteria (PNTM) infections, Mycobacterium avium and Mycobacterium abscessus, with the company’s inhaled liposomal ciprofloxacin products Linhaliq and Lipoquin.
Contract Research & Services > Clinical Trials > News
FDA lifts clinical hold on study of Multikine for head and neck cancer
By PBR Staff Writer
The US Food and Drug Administration (FDA) has lifted the clinical hold it had imposed on the CEL-SCI and Ergomed co-developed Multikine’s phase 3 head and neck cancer study.
Contract Research & Services > Clinical Trials > News
BMS’ kidney cancer drug met co-primary endpoint in CheckMate trial
By PBR Staff Writer
Bristol-Myers Squibb’s (BMS) kidney cancer drug Opdivo in combination with Yervoy (ipilimumab) has met the co-primary endpoint of objective response rate (ORR) against sunitinib in CheckMate -214 trial.
Contract Research & Services > Clinical Trials > News
Ophthotech’s wet-AMD drug Fovista fails in phase 3 AMD trial
By PBR Staff Writer
Ophthotech’s anti-PDGF therapy Fovista (pegpleranib) for treating wet age-related macular degeneration (AMD) has failed to meet the primary endpoint in a phase 3 trial.
Contract Research & Services > Clinical Trials > News
196-210 of 4334 results